05, 2017 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on discovering and ... a first-in-class glutaminase inhibitor, will be presented at the 2017 San Antonio Breast Cancer Symposium, December 5-9, 2017 in San Antonio, Texas.
News
- Updated Results from Phase I Study of CB-839 in Combination with Paclitaxel in Patients with ...
- Galectin drops 40% on negative NASH result
It's rarely ever a positive sign when a biotech has to resort to slicing and dicing data in order to find a positive result. ... for the presence of esophageal varices," said Stephen Harrison, one of lead investigators of the NASH-CX trial and medical director of Pinnacle Clinical Research in…
- SA biotech lining up talent, science and cash in march to market
The San Antonio-based biotech is expanding its leadership team. It's also preparing to launch new clinical trials in support of its lead CyPath Lung ...
- Axios Pro Rata
NanoCellect Biomedical, a San Diego-based developer of microfluidic cell sorting technologies for cell-based assays, has raised $10 million in Series B ... EagleTree Capital has led the acquisition of a majority stake in WaterFleet, a San Antonio, Texas-based provider of mobile water and…
- Meet some of San Antonio's most prolific inventors
The San Antonio Business Journal combed through available records to identify the city's most prolific inventors. The majority of the work patented is in information technology, while biotechnology is also well-represented. Many of the inventors have lived in cities other than San Antonio during…